Earnings Call Summary | Alector(ALEC.US) Q4 2023 Earnings Conference
Earnings Call Summary | Alector(ALEC.US) Q4 2023 Earnings Conference
The following is a summary of the Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript:
以下是 Alector, Inc. (ALEC) 2023 年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Alector ended Q4 2023 with $548.9 million. Raised $75 million from a financing offer in January 2024, extending cash runway through 2026.
Collaboration revenue for Q4 2023 was $15.2 million, up from Q4 2022. However, yearly collaboration revenue dropped to $97.1 million from $133.6 million in 2022.
Total R&D costs were reduced in Q4 2023, down to $47.7 million from $54.5 million in Q4 2022.
For 2023, Alector managed decreased overall R&D and general/administrative expenses compared to those in 2022. Revenue in 2024 is anticipated to range from $60 million to $70 million.
Alector 在 2023 年第四季度結束時收入爲 5.489 億美元。從2024年1月的融資要約中籌集了7500萬美元，將現金流延長至2026年。
2023年第四季度的協作收入爲1,520萬美元，高於2022年第四季度。但是，年合作收入從2022年的1.336億美元降至9,710萬美元。
2023年第四季度的總研發成本從2022年第四季度的5,450萬美元降至4,770萬美元。
與2022年相比，2023年，Alector的總體研發和一般/管理費用有所下降。預計2024年的收入將在6000萬美元至7,000萬美元之間。
Business Progress:
業務進展：
Alector continues their developmental progress in their TREM2 and progranulin programs as well as Alector Brain Carrier Technology.
Trial enrollments for therapy candidate latozinemab (INFRONT-3 Phase 3 trial) and AL002 (INVOKE-2 Phase 2 trial) were completed.
With GSK, Alector dosed the first participant in the Phase 2 clinical trial of AL101, PROGRESS-AD, for Alzheimer's disease.
The FDA granted Breakthrough Therapy designation to latozinemab for treatment of frontotemporal dementia with progranulin gene mutation.
Completed enrollment for long-term Phase 2b study of AL002 for Alzheimer's and received FDA clearance for another Alzheimer's treatment, AL101.
Made progress on latozinemab, reaching target enrollment for INFRONT-3 Phase 3 study.
Alector 繼續在 TREM2 和編程蛋白計劃以及 Alector Brain Carrier Technology 方面取得進展。
候選療法拉托津單抗（INFRONT-3 三期試驗）和 AL002（INVOKE-2 二期試驗）的試驗註冊已經完成。
Alector與葛蘭素史克合作，爲針對阿爾茨海默氏病的 AL101 二期臨床試驗 PROGRESS-AD 的第一位參與者服藥。
美國食品藥品管理局授予拉託津單抗突破性療法稱號，用於治療具有progranulin基因突變的額瞼癡呆。
完成了針對阿爾茨海默氏症的 AL002 長期2b期研究的入組，並獲得了美國食品藥品管理局對另一種阿爾茨海默氏症療法 AL101 的批准。
在拉託津單抗方面取得了進展，達到 INFRONT-3 3 期研究的目標入學人數。
More details: Alector IR
更多詳情： Alector IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。